Finanzen von Passage Bio Inc (PASG)PASGPassage Bio Inc

Evaluating the bottom line, Passage Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -169.09%, provide a clear picture of how effectively PASG converts its operational activities into shareholder value.

In the context of the broader market, PASG competes directly with industry leaders such as INTS and GDTC. With a market capitalization of $12.88M, it holds a leading position in the sector. When comparing efficiency, PASG's gross margin of N/A stands against INTS's N/A and GDTC's 1.81%. Such benchmarking helps identify whether Passage Bio Inc is trading at a premium or discount relative to its financial performance.

The financial performance shows significant losses, with a net income of -7,559,000 USD in Q1 2026 and a gross profit of 0 USD in Q2 2026. The current ratio is declining, now at 1.22, indicating potential liquidity issues.